Analisi facoltativa del prodotto
Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Accelerated balance sheet deleveraging and faster-than-anticipated realization of low-20s EBITDA margins following the separation of Food Ingredients.
Consolidated EBIT falls below USD 850 million over the next 18 months.
We rate International Flavors & Fragrances Inc. a Sell based on a Fair value of USD 43.00, representing 49.2% downside from the report-date price of USD 84.65 as of October 8, 2026,.2
We rate International Flavors & Fragrances Inc. a Sell. For an ordinary investor, this rating means capital is at substantial risk and existing positions should be closed or avoided, as current market pricing significantly overstates the normalized earning power and free cash flow generation of the restructured business.
On the report date of October 8, 2026, the shares traded at USD 84.65. This price stands 96.9% above our Fair value of USD 43.00, representing an implied downside of -49.2%. Even under our optimistic scenario, the report-date price trades 28.0% above our Potential value of USD 66.15. The stock trades at a forward price-to-earnings multiple of 17.67x, reflecting expectations of an immediate margin recovery that fail to reflect ongoing separation friction and high debt service obligations.
The main downside risk centers on input cost inflation and stranded overhead inertia stalling margin expansion. Management is targeting the elimination of two-thirds of stranded costs in year one post-closing. However, raw material, logistics, and energy inflation in Scent alongside contract pricing lags into 2027 could prevent operating margins from reaching modeled levels, while separation working capital friction of several hundred million dollars, strains debt reduction against $6,279 million in total debt. Investors would see this failure if FY2027 operating margin remains below 11.4% or if free cash flow generation falls short of debt reduction milestones.24
The main reason the business could exceed our baseline and move toward our Potential value of USD 66.15 is accelerated portfolio simplification and deleveraging. If IFF rapidly sheds stranded overhead after divesting Food Ingredients ($3,278 million in FY2025 sales) and applies more than $1 billion in transaction proceeds directly to debt paydown, operating margins could expand toward 16.5% while annual interest expense drops sharply. Supported by proprietary fragrance formulation moats and broad customer diversification where no single buyer exceeds 10% of revenue, cash flow per share would expand, though this constructive outcome remains secondary to our Fair value of USD 43.00 and the substantial valuation risk.47
Divestiture of Food Ingredients focuses IFF on Scent, Taste, and Health & Biosciences, which deliver ~43% gross margins and low-20s EBITDA margins alongside plans to eliminate two-thirds of stranded costs in year one,.4
Applying over $1 billion of divestiture proceeds toward debt paydown targets net debt to EBITDA between 2.0x and 2.5x by 2027, reducing annual interest burden and unlocking future share repurchases.4
Proprietary flavor and fragrance formulations create high customer switching costs, while broad commercial diversification ensures no single customer accounts for more than 10% of revenue,.47
Sell: The shares trade at a 96.9% premium to our Fair value of USD 43.00, reflecting market expectations of an aggressive margin recovery that underestimate high debt service costs, separation working capital drag, and delayed pricing power,.
International Flavors & Fragrances Inc. (IFF) is a global creator and manufacturer of specialty ingredients, formulations, and solutions utilized across the consumer goods, food, beverage, health, and personal care industries. The company operates through five principal segments: Scent, Taste, Health & Biosciences, Food Ingredients, and Pharma Solutions,,,,. IFF is currently executing a strategic portfolio simplification to focus exclusively on its high-innovation core businesses in Scent, Taste, and Health & Biosciences while divesting Food Ingredients and Pharma Solutions.
IFF serves consumer packaged goods manufacturers, luxury perfume houses, and industrial customers worldwide. In FY2025, consolidated revenue totaled $10,890 million, led by Food Ingredients ($3,278 million), Taste ($2,481 million), Scent ($2,479 million), Health & Biosciences ($2,283 million), and Pharma Solutions ($369 million). Customer concentration is highly dispersed, with no single customer accounting for more than 10% of consolidated sales across 2023, 2024, and 2025.
Geographically, IFF maintains an expansive international presence spanning mature and emerging markets. In FY2025, international sales outside the United States generated $7,815 million, representing 71.8% of consolidated net sales. Domestic operations within the United States generated $3,075 million, or 28.2% of total revenue. This broad global presence and diversified product portfolio support deep formulatory integration with major consumer brands.
Under a stressed multi-variable downside environment, RemainCo fails to realize anticipated margin gains post-divestiture. As energy, logistics, and raw material inputs surge while contractual price pass-through remains stalled, operating margins contract to 11.4%. Concurrently, transition friction surrounding the separation stand date consumes over $300M in working capital,, leaving total debt pinned near $6,279M. With pre-tax debt costs at 19.82% and WACC rising above 13.03%, free cash flow conversion collapses, driving intrinsic value toward the lower fair value boundary of $14.78.
Under the Bear case path, the business experiences persistent raw material, energy, and logistics inflation while contractual price pass-through remains sluggish across consumer accounts. Stranded corporate expenses linger unabsorbed following the Food Ingredients separation, while transition supply agreements generate protracted working capital leakage. Prolonged high balance sheet leverage sustains elevated capital costs and strains cash flow conversion, compressing fundamental intrinsic value.
Management identified modest increases in raw material, energy, and logistics costs in 2H 2026 with Scent most heavily impacted, noting that contract pricing recovery will lag into 2027. If input inflation escalates and customer pass-through fails, FY2027 operating margin falls 300 bps below the modeled 14.4% to below 11.4%.4
I cinque sviluppi che indebolirebbero la nostra tesi d'investimento.
Indicates failure of formula pricing pass-through and unabsorbed stranded overhead, depressing operating profit.
Attuale:12.30% in FY2026 forecast
Avviso se< 11.40% in FY2027
International Flavors & Fragrances Inc. possesses a narrow competitive moat built upon customer switching costs and proprietary formulation intangibles across its core Scent, Taste, and Health & Biosciences franchises. In specialty flavor and fragrance formulation, products typically constitute less than 5% of a consumer product's overall manufacturing cost, yet dictate its consumer appeal, scent signature, taste profile, and brand equity. Consequently, consumer packaged goods manufacturers face asymmetric risks when contemplating supplier changes, since reformulating an established consumer brand introduces substantial risk of customer churn with minimal cost savings. This dynamic is demonstrated by IFF's broad client diversification, where no single customer accounted for greater than 10% of consolidated net sales in 2023, 2024, or 2025.
The durability of IFF's competitive moat is further bolstered by proprietary synthesis methods, captive fragrance molecules, and tailored enzyme solutions. Through ongoing R&D reinvestment, IFF maintains dedicated perfumers and flavorists embedded directly within customer innovation workflows. While commodity basic materials peers like APD generate 25.54% operating margins in industrial gases, and coatings peers SHW and ECL earn 18.12% and 18.52%, IFF's pricing power is demonstrated by gross margins approaching ~43% in ongoing operations. The divestiture of capital-intensive Food Ingredients ($3,278M in FY2025) and Pharma Solutions ($369M) sharpens corporate focus onto these high-barrier specialty segments.
Nevertheless, IFF's moat remains classified as narrow rather than wide due to structural headwinds in capital efficiency and persistent cyclical exposure. Operating income was -$382M in FY2025, and historical return on invested capital has lingered around 3.10%, trailing the cost of capital. Although management has outlined a concrete timeline to eliminate two-thirds of stranded overhead within 12 months post-separation and the remainder in year two,, contractual pricing pass-through lags in Scent during inflationary phases, limit the company's ability to earn sustained excess economic returns beyond a 10-year horizon.
IFF currently exhibits an economic profit deficit, as its latest reported return on invested capital of 3.10% remains substantially below its moderate cost of equity of 9.24% and computed WACC of 11.03%. This historical spread compression stems from substantial goodwill and asset carrying values accumulated in prior acquisitions, alongside FY2025 operating losses of -$382M. Although RemainCo gross margins approach ~43% and EBITDA margins are guided to the low 20s, capital restructuring, debt repayment of over $1B, and the elimination of two-thirds of stranded overhead within 12 months are required before ROIC can sustainably exceed WACC across a multi-stage fade horizon.14
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
None of the valuation methods used to calculate Fair value relies on a separate assumption about how long the competitive advantage lasts.
The highlighted cell is Fair value when every assumption sits at its base level ($43.00). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $529.7M after modeled reinvestment of $285.2M, with terminal value at 69.7% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to revenue, reinvestment, or gross margin resets materially.
Under the Base case path, weighted at 60.0%, IFF successfully executes its portfolio refocusing into Scent, Taste, and Health & Biosciences. Gross margins normalize near the guided range while two-thirds of stranded overhead expenses are removed within the first twelve months post-separation. Capital expenditures moderate, and divestiture proceeds facilitate meaningful balance sheet deleveraging, leading to Fair value of $43.00 and an implied return of -49.2% against $84.65.
An operational beat across quarterly operating income and cash generation confirms that productivity initiatives and formula pricing are offsetting input inflation ahead of expectations, improving the risk profile relative to Fair value $43.00.
In-line financial results confirm that while operational transformation proceeds as planned, the stock price $84.65 already prices in an aggressive multi-year recovery that substantially exceeds our Fair value $43.00, leaving -49.2% negative.
An earnings miss confirms operational vulnerability to input cost spikes and stranded overhead friction, accelerating fundamental convergence toward our Fair value $43.00.
Earnings quality is currently undergoing transition as reported results reflect portfolio deconsolidation and non-operating separation expenses. True economic cash conversion is masked by temporary working capital friction stemming from transition service agreements, accounts receivable arrangements, and precautionary inventory stockpiling ahead of the separation stand date. Operating earnings quality will be validated by the degree to which gross margin expansion reflects underlying product mix improvements rather than transitory price timing, and whether operating cash flows rebound as separation agreements terminate.
Consensus estimate revisions following recent reporting have trended downward for annual earnings and sales, reflecting both the deconsolidation of divested units and near-term margin compression across Scent driven by raw material and logistics cost increases alongside formula pricing lag. Revisions underscore that Wall Street expectations are gradually recalibrating toward normalized post-separation operating reality.
Failure to eliminate corporate overhead will depress ongoing EBITDA margins and reduce net income conversion.
Cash flow generation is undergoing structural re-anchoring. FY2025 cash flow from operations was $850M with free cash flow of $254M after $594M in capex. For FY2026, operating cash flow faces interim friction of a couple hundred million dollars due to transition service agreements, accounts receivable delays, and inventory builds ahead of the Q1 2027 separation stand date,. Once these operational separation agreements terminate, working capital will normalize, allowing free cash flow conversion to accelerate toward $728M+ by FY2027.456
Historical ROIC was severely depressed at 3.10% following FY2025 operating losses of -$382M and net losses of -$361M on an inflated invested capital base. However, the trajectory is improving as the divestiture of capital-intensive Food Ingredients removes low-margin assets, while two-thirds of stranded overhead is eliminated in year one, expanding projected operating margin from 12.30% in FY2026 toward 15.83% by FY2030.
Current ROIC of 3.10% trails the computed WACC of 11.03% by approximately 793 bps, reflecting an ongoing destruction of economic value on legacy capital. Even against the moderate cost of equity of 9.24%, returns remain deeply inadequate, requiring the execution of planned debt reduction and margin expansion to bridge the deficit.
Exiting Food Ingredients ($3,278M in FY2025) lifts RemainCo gross margin toward ~43% and guided into the low 20s.
| Ricavi | 1.954.000.000 USD |
|---|---|
| Costo del venduto | 1.101.000.000 USD |
| Utile lordo | 853.000.000 USD |
| Costi operativi | 695.000.000 USD |
| Reddito operativo | 158.000.000 USD |
| Voci non operative e imposte | -108.000.000 USD |
| Utile netto | 50.000.000 USD |
| Attività totali | 25.539.000.000 USD |
|---|---|
| Disponibilità liquide | 590.000.000 USD |
| Attività correnti | 5.594.000.000 USD |
| Passività totali | 11.353.000.000 USD |
| Passività correnti | 3.933.000.000 USD |
| Patrimonio netto | 14.186.000.000 USD |
| Utile netto | 243.000.000 USD |
|---|---|
| Afflusso operativo | 1.335.000.000 USD |
| Ammortamenti e svalutazioni | 1.015.000.000 USD |
| Compensi basati su azioni | 77.000.000 USD |
| Flusso di cassa operativo | 1.070.000.000 USD |
| Deflusso operativo | 265.000.000 USD |
| Liquidità disponibile | 2.131.000.000 USD |
| Liquidità iniziale | 735.000.000 USD |
| Afflusso da investimenti | 326.000.000 USD |
| Deflusso da finanziamenti | 1.606.000.000 USD |
| Dividendi pagati | 514.000.000 USD |
| Rimborso netto del debito | 1.030.000.000 USD |
| Altre attività di finanziamento | 62.000.000 USD |
| Effetto dei tassi di cambio | 54.000.000 USD |
| Liquidità finale | 469.000.000 USD |
| Flusso da investimenti | 326.000.000 USD |
| Flusso da finanziamenti | -1.606.000.000 USD |
Fonte: SEC EDGAR · Depositato 2026-02-27 · SEC EDGAR
| Ricavi per segmento operativo | Ricavi | Quota | a/a |
|---|---|---|---|
| Food Ingredients | 3,3 Mld USD | 30,1% | -2,6% |
| Taste | 2,5 Mld USD | 22,8% | 2,2% |
| Scent | 2,5 Mld USD | 22,8% | 1,6% |
| Health And Biosciences | 2,3 Mld USD | 21% | 3,6% |
| Pharma Solutions | 369 Mln USD | 3,4% | -64,8% |
Fonte: SEC EDGAR · Depositato 2026-02-27 · SEC EDGAR
| Ricavi per area geografica | Ricavi | Quota | a/a |
|---|---|---|---|
| EMEA | 3,7 Mld USD | 34,2% | -2,9% |
| North America | 3,2 Mld USD | 29,3% | -7,1% |
| Asia | 2,5 Mld USD | 23,4% | -6,8% |
| Latin America | 1,4 Mld USD | 13,1% | -3,5% |
Dati finanziari puntuali utilizzati nell’analisi del 2026-10-08.
| Periodo | Ricavi | EBITDA | Utile netto | Flusso di cassa operativo | Flusso di cassa libero | Capex | Ammortamenti e svalutazioni | Compensi basati su azioni | Riacquisti di azioni | Dividendi pagati | Emissione netta di debito | Flusso da investimenti | Flusso da finanziamenti | Liquidità iniziale | Liquidità finale | Liquidità e investimenti | Debito totale | Margine operativo | ROIC | WACC | Differenziale ROIC−WACC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | 3,1 Mld USD | 679,2 Mln USD | 405 Mln USD | 550,1 Mln USD | 423,7 Mln USD | 126,4 Mln USD | 102,5 Mln USD | 24,6 Mln USD | 127,4 Mln USD | 184,9 Mln USD | — | -355,5 Mln USD | -34,4 Mln USD | — | 324 Mln USD | 324,3 Mln USD | 1,3 Mld USD | 17,7% | — | 5,4% | — |
| 2017-12-31 | 3,4 Mld USD | 720,4 Mln USD | 295,7 Mln USD | 390,8 Mln USD | 261,8 Mln USD | 129 Mln USD | 118 Mln USD | 26,6 Mln USD | 58,1 Mln USD | 206,1 Mln USD | — | -299,9 Mln USD | -42,6 Mln USD | 324 Mln USD | 368 Mln USD | 368 Mln USD | 1,6 Mld USD | 16,3% | — | 5,3% | — |
| 2018-12-31 | 4 Mld USD | 754,1 Mln USD | 339,8 Mln USD | 437,6 Mln USD | 267,5 Mln USD | 170,1 Mln USD | 173,8 Mln USD | 29,4 Mln USD | 15,5 Mln USD | 230,2 Mln USD | — | -5 Mld USD | 4,9 Mld USD | 368 Mln USD | 649 Mln USD | 634,9 Mln USD | 4,6 Mld USD | 14,7% | — | 4,9% | — |
| 2019-12-31 | 5,1 Mld USD | 1 Mld USD | 454 Mln USD | 699 Mln USD | 463 Mln USD | 236 Mln USD | 323 Mln USD | 34 Mln USD | 0 USD | 314 Mln USD | — | -226 Mln USD | -505 Mln USD | 649 Mln USD | 624 Mln USD | 607 Mln USD | 4,4 Mld USD | 12,9% | — | 4,2% | — |
| 2020-12-31 | 5,1 Mld USD | 898 Mln USD | 365 Mln USD | 714 Mln USD | 522 Mln USD | 192 Mln USD | 325 Mln USD | 36 Mln USD | 0 USD | 323 Mln USD | — | -187 Mln USD | -512 Mln USD | 624 Mln USD | 660 Mln USD | 650 Mln USD | 4,4 Mld USD | 11,1% | — | 3,6% | — |
| 2021-12-31 | 11,7 Mld USD | 1,8 Mld USD | 268 Mln USD | 1,4 Mld USD | 1 Mld USD | 393 Mln USD | 1,2 Mld USD | 54 Mln USD | — | 667 Mln USD | — | -18 Mln USD | -1,3 Mld USD | 660 Mln USD | 716 Mln USD | 711 Mln USD | 11 Mld USD | 5,0% | — | 4,7% | — |
| 2022-12-31 | 12,4 Mld USD | -110 Mln USD | -1,9 Mld USD | 397 Mln USD | -107 Mln USD | 504 Mln USD | 1,2 Mld USD | 49 Mln USD | — | 810 Mln USD | -344 Mln USD | 745 Mln USD | -1,2 Mld USD | 716 Mln USD | 552 Mln USD | 483 Mln USD | 10,6 Mld USD | -10,7% | — | — | — |
| 2023-12-31 | 11,5 Mld USD | -996 Mln USD | -2,6 Mld USD | 1,5 Mld USD | 952 Mln USD | 503 Mln USD | 1,1 Mld USD | 65 Mln USD | 0 USD | 826 Mln USD | -941 Mln USD | 558 Mln USD | -1,9 Mld USD | 552 Mln USD | 709 Mln USD | 703 Mln USD | 10 Mld USD | -18,4% | — | — | — |
| 2024-12-31 | 11,5 Mld USD | 1,6 Mld USD | 243 Mln USD | 1,1 Mld USD | 602 Mln USD | 463 Mln USD | 1 Mld USD | 77 Mln USD | 0 USD | 514 Mln USD | -1 Mld USD | 326 Mln USD | -1,6 Mld USD | 735 Mln USD | 469 Mln USD | 469 Mln USD | 8,9 Mld USD | 6,7% | — | 7,7% | — |
| 2025-12-31 | 10,9 Mld USD | 779 Mln USD | -361 Mln USD | 850 Mln USD | 254 Mln USD | 594 Mln USD | 962 Mln USD | 88 Mln USD | 38 Mln USD | 409 Mln USD | -2,6 Mld USD | 2,3 Mld USD | -3,1 Mld USD | 471 Mln USD | 590 Mln USD | 590 Mln USD | 5,6 Mld USD | -3,5% | — | — | — |
International Flavors & Fragrances Inc. (IFF) trades at 17.7x forward earnings against a peer median of 21.3x. Its EV/EBITDA of 14.2x compares with a peer median of 18.5x. The comparison uses 4 peers: PPG Industries Inc., The Sherwin-Williams Company, Ecolab Inc. and Air Products and Chemicals Inc., as of 2026-10-07 to 2026-10-08.
The basic materials specialty chemical peer group benchmark exhibits an industry capex-to-revenue ratio of 0.041 (4.1%) and a capex-to-depreciation ratio of 1.55, indicating disciplined capital deployment following peak capacity additions. IFF's FY2025 capex of $594M on revenue of $10,890M represented 5.45% of sales,, and is being rationalized to 3.8% post-divestiture.46
In an industry upcycle, broad CPG volume expansion drives surging demand for premium fine fragrances, natural flavors, and bio-based ingredients. Customers accelerate product reformulation and new SKU introductions, absorbing specialty ingredient cost increases readily. Operating leverage across formulation facilities expands gross margins toward 43% and EBITDA margins into the low 20s.
During an industry downcycle, consumer packaged goods manufacturers experience volume elasticity pressure, prompting retail shelf-space rationalization, inventory destocking, and ingredient down-trading. Specialty chemical producers face raw material and energy cost spikes that cannot be immediately recovered due to annual or multi-quarter contractual pricing lags, compressing operational margins.
IFF is repositioning itself from a sprawling conglomerate into a focused specialty solutions provider. While basic materials peers like APD command 25.54% operating margins in industrial gases,, and coatings peers SHW and ECL deliver 18.12% and 18.52% operating margins, IFF's FY2025 reported operating loss of -$382M reflects historical restructuring. Post-separation, RemainCo targets low-20s EBITDA margins supported by 71.8% non-US geographic reach.3467
Given that IFF trades at $84.65 as of 2026-10-08, representing a 96.86% premium over our fundamental Fair value midpoint of $43.00, the stock warrants a Sell rating. Implied downside of -49.20% indicates that market pricing already over-anticipates flawless execution of portfolio simplification, stranded cost removal, and deleveraging while underpricing transition friction and high debt burdens of $6,279M. Consequently, recommended portfolio allocation is 0%.24
Risk management under a Sell rating centers on capital preservation and eliminating uncompensated downside exposure. Investors should recognize that IFF's total debt of $6,279M and pre-tax debt costs of 19.82% create structural balance sheet fragility. Any delays in closing divestitures, higher-for-longer benchmark interest rates, or working capital drains associated with the Q1 2027 stand date will disproportionately impair equity value. Capital should be reallocated to specialty materials peers trading at reasonable valuation multiples.
The stock trades at USD 84.65, which represents a 96.9% premium to our Fair value of USD 43.00. With an unadjusted FY2025 operating loss of USD -382 million and total debt of USD 6,279 million, there is no margin of safety.26
Capital allocation is heavily constrained by balance sheet deleveraging commitments. While dividend distributions are maintained, debt reduction and separation working capital friction of several hundred million dollars will prioritize debt retirement over dividend growth.4
Headline sales contract substantially as Food Ingredients ($3,278 million in FY2025 revenue) is deconsolidated. While RemainCo targets 2% to 4% growth, raw material and energy cost inflation in Scent creates near-term margin pressure.47
We recommend selling or avoiding shares of International Flavors & Fragrances Inc. at the report-date price of USD 84.65. The market price stands 96.9% above our Fair value of USD 43.00, implying a -49.2% downside. Current valuation prices in an aggressive, flawless post-separation recovery that ignores elevated debt service and near-term margin friction.2
While portfolio streamlining around Scent, Taste, and Health & Biosciences improves business quality, separation working capital leakage and lag in pricing recovery make the risk-reward profile distinctly unfavorable for new and existing capital.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Total debt is $6,279M, pre-tax cost of debt is 19.82%, and credit conditions remain constrained. If divestiture proceeds are delayed or credit spreads widen, WACC expands 200 bps above the computed 11.03% to over 13.03%.12
Current forward P/E is 17.67x while peer median is 21.25x and cyclical peer PPG trades at 12.20x. If RemainCo fails to demonstrate sustainable margin expansion and organic volume compounding, market valuation derates 20% below the modeled 18.0x terminal P/E down to 14.4x.2
Attuale:$6,279M as of 2026-10-08
Avviso se> $5,500M after FY2027
Confirms protracted working capital leakage from separation agreements and inventory builds ahead of stand date.
Attuale:$850M in FY2025
Avviso se< $850M in FY2026
Signals customer destocking and market share loss in core Scent and Taste categories.
Attuale:2% to 4% guided for FY2026
Avviso se< -5% in FY2027
Signals severe unhedged raw material and logistics cost inflation compressing unit economics.
Attuale:~43% ongoing baseline
Avviso se< 40.0% in FY2026-FY2027
| Stranded overhead costs and IT separation friction post-divestiture | high | 12-24 months | Execution of targeted restructuring to eliminate two-thirds of stranded expenses within year one and remainder in year two.4 |
| Working capital absorption and supply chain inventory buffers ahead of separation stand date | medium | 3-9 months | Transitory management of transition service agreements through early Q1 2027 followed by inventory normalization.4 |
Under the moderate discount rate, 14,07 USD comes from forecast-period earnings and 51,98 USD from the long-term value, totaling 66,05 USD.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and terminal value at WACC, then adjust for signed net debt per current share.
Discounted forecast-period cash flows (12,03 USD) plus discounted terminal value (27,72 USD) minus signed per current share (19,77 USD) equals the 19,97 USD lens value shown above. Negative net debt is , so subtracting it raises value.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Value each distinct segment, subtract corporate overhead and net debt, add probability-weighted optionality, and divide by diluted shares.
Solve for the growth rate that makes the model value equal the report-date share price.
Project revenue, apply a terminal EV/revenue multiple, discount enterprise value, subtract net debt, and divide by diluted shares.
Under the Bull case path, assigned a 15.0% probability, RemainCo accelerates operational efficiencies to reach upper-tier specialty peer margins. Formula pricing resets outpace raw material cost inflation, emerging market volume growth in fine fragrance and taste compounds accelerates, and stranded overhead is extinguished rapidly. Rapid debt retirement restores credit strength, driving valuation to Potential value of $66.15 and an implied return of -21.9% relative to $84.65.
Lags in contractual pricing recovery squeeze division gross margins and compress operating cash flow.
Excessive inventory builds and receivables delays drain free cash flow and restrict capital deployment.
Retiring debt lowers interest expenses and reduces cost of capital, expanding equity value.
Organic volume gains confirm customer switching barriers and validate formulatory intangible moats.
| $8.25B |
| $8.55B |
| $8.84B |
| Revenue growth | -29.8% | 3.9% | 3.9% | 3.7% | 3.4% |
| Operating margin | 12.3% | 14.4% | 15.6% | 15.7% | 15.8% |
| Operating income | $939.96M | $1.14B | $1.29B | $1.35B | $1.40B |
| Tax rate | 13.3% | 15.0% | 18.0% | 18.0% | 18.0% |
| NOPAT | $814.85M | $971.52M | $1.06B | $1.10B | $1.15B |
| Reinvestment | $285.20M | $242.88M | $211.46M | $220.69M | $229.61M |
| Reinvestment rate (of NOPAT) | 35.0% | 25.0% | 20.0% | 20.0% | 20.0% |
| Free cash flow to firm | $529.65M | $728.64M | $845.83M | $882.77M | $918.42M |
| Food Ingredients revenue | $2.30B | $2.39B | $2.48B | $2.57B | $2.66B |
| Taste revenue | $1.74B | $1.81B | $1.88B | $1.95B | $2.01B |
| Scent revenue | $1.74B | $1.81B | $1.88B | $1.95B | $2.01B |
| Health and Biosciences revenue | $1.60B | $1.66B | $1.73B | $1.79B | $1.85B |
| Pharma Solutions revenue | $259.05M | $269.14M | $279.63M | $289.92M | $299.83M |
| Terminal growth | 2.5% | 2.5% | 2.5% | 2.5% | 2.5% |
Capital allocation is entering a pivotal transition phase. Historical capital deployment was impaired by debt-financed M&A, leaving total debt at $6,279M and pre-tax debt costs at 19.82%. Management's updated capital policy prioritizes balance sheet repair, targeting over $1B in divestiture proceeds directly toward debt reduction to achieve net debt to EBITDA between 2.0x and 2.5x by end of FY2027. Reinvestment is prioritized for high-margin R&D in Scent and Taste with capex guided to normalize around 3.8% of sales. Share repurchases are budgeted at $500M in 2H 2026 and up to $2B through 2027, contingent upon meeting deleveraging thresholds.
Transition supply agreements and stand date preparations in early Q1 2027 absorb several hundred million dollars in working capital,.
Elevates FY2026 reinvestment rate to 35% of NOPAT and delays discretionary cash return until post-separation stabilization.
Total debt of $6,279M and pre-tax debt cost of 19.82% drive WACC to 11.03%.
Intense debt service burdens equity holders until transaction proceeds exceeding $1B are applied to debt retirement.
| Margine |
|---|
| IFF | International Flavors & Fragrances Inc. | $21.6B | 17.7x | 2.0x | 14.2x | -5.5% | — |
| PPG | PPG Industries Inc. | $23.4B | 12.2x | 1.4x | 10.9x | 19.3% | 14.0% |
| SHW | The Sherwin-Williams Company | $76.5B | 23.2x | 3.1x | 19.3x | 65.1% | 18.1% |
| ECL | Ecolab Inc. | $78.0B | 29.5x | 4.6x | 21.2x | 22.0% | 18.5% |
| APD | Air Products and Chemicals Inc. | $61.9B | 19.3x | 4.9x | 17.7x | 0.0% | 25.5% |
| Volatility in petrochemical feedstocks, energy, and logistics | negative | Persistent inflation in logistics and raw material inputs creates periodic margin pressure that requires multi-quarter customer contract pricing renegotiations to recoup,. |
| < $43.00 (At or below Fair Value Midpoint) | Re-evaluation threshold | A price decline below Fair value midpoint would provide an adequate margin of safety to warrant re-underwriting the investment thesis. |
| Reassess transition working capital leakage and reduce debt repayment expectations. |
| Net Debt to EBITDA | Ratio exceeding 3.5x as of year-end FY2026 | Recognize delayed deleveraging timeline and expand cost of capital assumption. |
| Gross Margin | Consolidated gross margin failing to maintain 41.0% in 2H 2026 | Validate persistent input cost inflation and pricing pass-through failure in Scent. |
